Loading organizations...
§ Private Profile · Lausanne, Vaud, Switzerland
manufactures ex vivo blood platelets from stem cells for on-demand production, targeting thrombocytopenia and regenerative medicine.
Hemostod, based in Lausanne, Switzerland, manufactures ex vivo blood platelets from engineered stem cells using proprietary microfluidic bioreactor technology, enabling on-demand production in just a few hours. The company develops donor-free, universal platelets as a vital alternative to traditional blood donor transfusions, addressing critical shortages and contamination risks for allo-immunized and HSCT patients in the onco-hematology market, while also targeting thrombocytopenia treatment, tissue-targeted drug delivery, and regenerative medicine applications. Co-founded in 2020 by Faouzi Khechana, the leadership team features Executive Chairman Laurent Massuyeau and CSO Nicoletta Sorvillo. Currently in preclinical stage, Hemostod has raised CHF 4.9 million through venture capital and grants, with key investors including Polytech Ventures, Orenok Holdings, and Lichtsteiner Foundation. With 9 employees, the company plans a Pre-IND meeting with the FDA and is establishing commercial-scale production capabilities, targeting first human transfusion trials for 2025.
Hemostod has raised $6.0M across 2 funding rounds.
Hemostod has raised $6.0M in total across 2 funding rounds.
Hemostod has raised $6.0M across 2 funding rounds. Most recently, it raised $5.4M Seed Extension in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $5.4M Seed Plus | Laurent Massuyeau, Guillaume Dubray | Sabina Sperisen | Announced |
| Jun 11, 2024 | $560K Debt Financing | Foundation For Technological Innovation | — | Announced |
Hemostod has raised $6.0M in total across 2 funding rounds.
Hemostod's investors include Laurent Massuyeau, Guillaume Dubray, Sabina Sperisen, Foundation for Technological Innovation.